Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study

Truelsena, 2005, Cost of stroke in Europe, Eur J Neurol, 12, 78, 10.1111/j.1468-1331.2005.01199.x

Hacke, 2004, Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials, Lancet, 363, 768, 10.1016/S0140-6736(04)15692-4

Adams, 2003, Guidelines for the early management of patients with ischaemic stroke: a scientific statement from the Stroke Council of the American Stroke Association, Stroke, 34, 1056, 10.1161/01.STR.0000064841.47697.22

2003, European stroke initiative recommendations for stroke management—update 2003, Cerebrovasc Dis, 16, 311, 10.1159/000072554

Clark, 1999, Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke, JAMA, 282, 2019, 10.1001/jama.282.21.2019

Clark, 2000, The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators, Stroke, 31, 811, 10.1161/01.STR.31.4.811

Hacke, 1995, Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS), JAMA, 274, 1017, 10.1001/jama.1995.03530130023023

Hacke, 1998, Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators, Lancet, 352, 1245, 10.1016/S0140-6736(98)08020-9

1995, The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, N Engl J Med, 333, 1581

Saver, 2004, Number needed to treat estimates incorporating effects over the whole range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke, Arch Neurol, 61, 1066, 10.1001/archneur.61.7.1066

Wardlaw, 2000, Thrombolysis for acute ischaemic stroke, Cochrane Database Syst Rev, 2, CD000213

Wardlaw, 2003, Thrombolysis for acute ischaemic stroke, Cochrane Database Syst Rev, 3, CD000213

Anon

Larrue, 2001, Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II), Stroke, 32, 438, 10.1161/01.STR.32.2.438

Berger, 2001, Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic?, Stroke, 32, 1330, 10.1161/01.STR.32.6.1330

Newcombe, 1998, Two-sided confidence intervals for the single proportion: comparison of seven methods, Stat Med, 17, 857, 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E

Hill, 2005, Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study, CMAJ, 172, 1307, 10.1503/cmaj.1041561

Langhorne, 1995, A formal overview of stroke unit trials, Rev Neurol, 23, 394

Tanne, 1999, Initial clinical experience with i.v. tissue plasminogen activator for acute ischemic stroke. A multicentre survey, Neurology, 53, 424, 10.1212/WNL.53.2.424

Albers, 2000, Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study, JAMA, 283, 1145, 10.1001/jama.283.9.1145

Katzan, 2000, Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience, JAMA, 283, 1151, 10.1001/jama.283.9.1151

Lyden, 2006, Alteplase for acute stroke revisited: the first 10 years, Lancet Neurol, 5, 722, 10.1016/S1474-4422(06)70530-0

Kaste, 2003, Approval of alteplase in Europe: will it change stroke management?, Lancet Neurol, 2, 207, 10.1016/S1474-4422(03)00343-0